These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32463124)

  • 1. Incidence of vasoplegic syndrome after cardiac transplantation in patients treated with sacubitril/valsartan.
    Domínguez JM; García-Romero E; Pàmies J; Mirabet S; Gonzalez-Costello J; Spitaleri G; Perez-Villa F; Farrero M
    Clin Transplant; 2020 Aug; 34(8):e13994. PubMed ID: 32463124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARNI Pre-Operative Use and Vasoplegic Syndrome in Patients Undergoing Heart Transplantation or Left Ventricular Assist Device Surgery.
    Haider L; Hugon-Vallet E; Constantin JP; Riad Z; Sebbag L; Mewton N
    Med Sci (Basel); 2021 Dec; 10(1):. PubMed ID: 35076588
    [No Abstract]   [Full Text] [Related]  

  • 3. Vasoplegia from Continuous Flow Left Ventricular Assist Devices.
    Sathianathan S; Bhat G; Dowling R
    Curr Cardiol Rep; 2021 Jul; 23(8):101. PubMed ID: 34196837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoplegia Following Orthotopic Heart Transplantation: Prevalence, Predictors and Clinical Outcomes.
    Batchelor RJ; Wong N; Liu DH; Chua C; William J; Tee SL; Sata Y; Bergin P; Hare J; Leet A; Taylor AJ; Patel HC; Burrell A; McGiffin D; Kaye DM
    J Card Fail; 2022 Apr; 28(4):617-626. PubMed ID: 34974975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and Impact of On-Cardiopulmonary Bypass Vasoplegia During Heart Transplantation.
    Truby LK; Takeda K; Farr M; Beck J; Yuzefpolskaya M; Colombo PC; Topkara VK; Mancini D; Naka Y; Takayama H
    ASAIO J; 2018; 64(1):43-51. PubMed ID: 28777136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices.
    Asleh R; Alnsasra H; Daly RC; Schettle SD; Briasoulis A; Taher R; Dunlay SM; Stulak JM; Behfar A; Pereira NL; Frantz RP; Edwards BS; Clavell AL; Kushwaha SS
    J Am Heart Assoc; 2019 Nov; 8(22):e013108. PubMed ID: 31701791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profound Vasoplegia During Sacubitril/Valsartan Treatment After Heart Transplantation.
    Almufleh A; Mielniczuk LM; Zinoviev R; Moeller A; Davies RA; Stadnick E; Chan V; Chih S
    Can J Cardiol; 2018 Mar; 34(3):343.e5-343.e7. PubMed ID: 29398176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty.
    Cacciatore F; Amarelli C; Maiello C; Mattucci I; Salerno G; Di Maio M; Palmieri V; Curcio F; Pirozzi F; Mercurio V; Benincasa G; Golino P; Bonaduce D; Napoli C; Abete P
    ESC Heart Fail; 2020 Apr; 7(2):757-762. PubMed ID: 32074411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of Left Ventricular Assist Device Infections With Cardiac Transplant Outcomes.
    Parikh A; Halista M; Raymond S; Feinman J; Mancini D; Mitter S; Barghash M; Trivieri M; Contreras J; Taimur S; Roldan J; Murphy J; Pawale A; Anyanwu A; Moss N; Lala A; Pinney S
    Am J Cardiol; 2021 Dec; 160():67-74. PubMed ID: 34615608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraoperative vasoplegic syndrome in patients with fulminant myocarditis on ventricular assist device placement.
    Ezaka M; Maeda T; Ohnishi Y
    J Anesth; 2019 Apr; 33(2):304-310. PubMed ID: 30863956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era.
    Patarroyo M; Simbaqueba C; Shrestha K; Starling RC; Smedira N; Tang WH; Taylor DO
    J Heart Lung Transplant; 2012 Mar; 31(3):282-7. PubMed ID: 22112993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence, outcomes and predictors.
    de Waal EEC; van Zaane B; van der Schoot MM; Huisman A; Ramjankhan F; van Klei WA; Marczin N
    BMC Anesthesiol; 2018 Dec; 18(1):185. PubMed ID: 30526494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoplegia after heart transplantation: outcomes at 1 year.
    Chan JL; Kobashigawa JA; Aintablian TL; Li Y; Perry PA; Patel JK; Kittleson MM; Czer LS; Zarrini P; Velleca A; Rush J; Arabia FA; Trento A; Esmailian F
    Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):212-217. PubMed ID: 28459983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of sacubitril-valsartan in cancer patients with heart failure.
    Martín-Garcia A; López-Fernández T; Mitroi C; Chaparro-Muñoz M; Moliner P; Martin-Garcia AC; Martinez-Monzonis A; Castro A; Lopez-Sendon JL; Sanchez PL
    ESC Heart Fail; 2020 Apr; 7(2):763-767. PubMed ID: 32022485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants and Outcomes of Vasoplegia Following Left Ventricular Assist Device Implantation.
    Tecson KM; Lima B; Lee AY; Raza FS; Ching G; Lee CH; Felius J; Baxter RD; Still S; Collier JDG; Hall SA; Joseph SM
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29773577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
    Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylene Blue Does Not Improve Vasoplegia After Left Ventricular Assist Device Implantation.
    Saha A; Jennings DL; Ning Y; Kurlansky P; Miltiades AN; Spellman JL; Sanchez J; Yuzefpolskaya M; Colombo PC; Takayama H; Naka Y; Takeda K
    Ann Thorac Surg; 2021 Mar; 111(3):800-808. PubMed ID: 32758558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.